Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...

Starting next year, Medicare recipients will see a $2,000 out-of-pocket cap on some prescription drugs as part of several new provisions coming in 2025. Starting in 2025, Medicare recipients will ...

These drugs are primarily used to manage Type 2 diabetes, but their effectiveness in weight loss has opened new doors for treating obesity. By slowing down digestion, GLP-1 drugs help people feel ...

The history of breakthrough weight loss medicines is riddled with tragic results. Based on the histories of phen-fen and ...

Researchers at Université de Montréal’s affiliated hospital research center (CRCHUM) suggest that targeting these molecules could offer new ... obesity and metabolic disorders such as type 2 diabetes, ...

In 2021, the USFDA approved Wegovy, another semaglutide-based drug from Novo Nordisk ... have joined the ranks of high-demand therapies for obesity care. While the new therapies have shown to reduce ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal ...